ArticleCancer cell2018
A-to-I RNA Editing: An Overlooked Source of Cancer Mutations.
Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- ENDONUCLEASE V: FROM TRANSCRIPTOME REGULATOR TO CHEMICAL BIOLOGY TOOL.ChemistryEurope · 2026Article
- A Global Assessment of the Transcription-Dependent Single Nucleotide Variants Relies on the Characteristics of RNA-Sequencing Technologies.Biomolecules · 2026Article
- Review
- Nomogram Based on A-To-I RNA Editing for Predicting Overall Survival in Patients With Breast Cancer.Journal of cellular and molecular medicine · 2025Article
- Advances in A-to-I RNA editing in cancer.Molecular cancer · 2024Review
- ADAR-Mediated A>I(G) RNA Editing in the Genotoxic Drug Response of Breast Cancer.International journal of molecular sciences · 2024Review
- ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner.BMC biology · 2024Article
- Cell-free multi-omics analysis reveals potential biomarkers in gastrointestinal cancer patients' blood.Cell reports. Medicine · 2023Article
- A novel, effective machine learning-based RNA editing profile for predicting the prognosis of lower-grade gliomas.Heliyon · 2023Article
- Article
- Single-Cell Analysis in Lung Adenocarcinoma Implicates RNA Editing in Cancer Innate Immunity and Patient Prognosis.Cancer research · 2023Article
- Site-directed RNA editing by harnessing ADARs: advances and challenges.Functional & integrative genomics · 2022Review
- Inhibiting DNA methylation and RNA editing upregulates immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer.Journal for immunotherapy of cancer · 2022Article
- A-to-I nonsynonymous RNA editing was significantly enriched in the ubiquitination site and correlated with clinical features and immune response.Scientific reports · 2022Article
- Current challenges and best practices for cell-free long RNA biomarker discovery.Biomarker research · 2022Review
- Functions and consequences of AID/APOBEC-mediated DNA and RNA deamination.Nature reviews. Genetics · 2022Review
- Development and Validation of a Four Adenosine-to-Inosine RNA Editing Site-Relevant Prognostic Signature for Assessing Survival in Breast Cancer Patients.Frontiers in oncology · 2022Article
- Conservation of A-to-I RNA editing in bowhead whale and pig.PloS one · 2021Article
- A-to-I RNA Editing in Cancer: From Evaluating the Editing Level to Exploring the Editing Effects.Frontiers in oncology · 2020Review
- Systematically Characterizing A-to-I RNA Editing Neoantigens in Cancer.Frontiers in oncology · 2020Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA editing is a source of transcriptomic diversity, mainly in non-coding regions, and is found to be altered in cancer. In this issue of Cancer Cell, Peng et al. show that RNA editing events are manifested at the proteomic levels and are a source of cancer protein heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.